Back to search
FDAFDA · Food and drugs·Recall number D-0155-2025

Duloxetine Delayed-Release Capsules USP, 30 mg, Rx only, 30 count bottles, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories NDC 68001-414-04

Published January 1, 2025 · Recall initiated: December 6, 2024

Summary

FDA records drug Class II recall D-0155-2025, published January 1, 2025 and initiated December 6, 2024. Recalling firm: Amerisource Health Services LLC; Status: Ongoing; Reported quantity: 21,262 bottles; Lot: Lot DT3023029A Exp 02/28/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Amerisource Health Services LLC
Distributor
Nationwide in the USA
Lot
Lot DT3023029A Exp 02/28/2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Duloxetine Delayed-Release Capsules USP, 30 mg, Rx only, 30 count bottles, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories NDC 68001-414-04 recalled?

Yes. FDA published recall D-0155-2025 on January 1, 2025. Reported hazard: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.

What should I do if I have this product?

Voluntary: Firm initiated · Letter